Myelofibrosis Research: New data shed light on potential advantages of pacritinib for patients with myelofibrosis

Posted on Posted in Cancer News, Myelofibrosis News

(SOURCE: AMERICAN SOCIETY OF HEMATOLOGY) – Pacritinib, currently on hold by the FDA, appears to be more effective in reducing spleen volume; twice-daily dose improves symptoms. This analysis comes from data before the clinical hold. Compared with standard therapy, pacritinib significantly reduces spleen size among people with myelofibrosis who have very low levels of platelets, according to […]